Definitive Contract HHSN266200400042C
- Not listed
- This is a $9,983,467.70 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of Chicago to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. The contract has a period of performance through April 30, 2026 and was originally solicited through a Broad Agency Announcement issued by NIAID in 2018. The University of Chicago is collaborating with the IIT Research Institute and the University of...
- This firm-fixed-price purchase order, valued at $24,455.00, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of Chicago for the "ARIC Anthrax Study". The contract, which does not have a set-aside designation, is for the University of Chicago to perform "other functions" related to the study. The University of Chicago is a renowned private research institution that frequently receives federal funding through contracts and...
- This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to the University of Texas Health Science Center at San Antonio (UTHSCSA) to provide pre-clinical models and testing services for the development of medical countermeasures against viral, bacterial, and fungal pathogens. The contract is an indefinite delivery vehicle (IDV) valued at up to $146.3 million over 7 years, under which...
- This federal contract award, with an ID of 75N93019C00076, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the University of Chicago for the "Bioinformatics Resource Centers for Infectious Diseases" service. The base contract is valued at $6,438,323, with a ceiling value of $42,775,844.50 and a period of performance through September 14, 2024. This contract was not set aside for any specific business category. The University of...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. government. The contract, valued at $659,747.55, was awarded to the University of Texas Health Science Center at San Antonio (UTHSCSA) to provide animal models of infectious diseases. This contract is a delivery order under NIAID's larger "Animal Models of Infectious Diseases 2010-2017" indefinite delivery vehicle (IDV), which has a potential...
- The U.S. Department of Health and Human Services, National Institute of Allergy and Infectious Diseases (NIAID) awarded a Delivery Order contract to the University of Georgia Research Foundation, Inc. (UGA Research Foundation) for "ANIMAL MODELS OF INFECTIOUS DISEASES". This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) awarded to UGA Research Foundation in July 2024, valued up to $146.3 million over 7 years. The contract focuses on developing and employing...
- This federal contract award, valued at $12,612,049, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to the University of Pittsburgh. The contract is for research and development related to infectious disease models, including the provision of small animal models, non-human primate models, animal replacement models, and specialized reagents. This contract is part of a larger $146.3 million...
- This federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to the University of Georgia Research Foundation, Inc. (UGA Research Foundation). The $211,731 Firm Fixed Price Delivery Order falls under the NIAID Animal Models of Infectious Diseases 2010-2017 Indefinite Delivery Contract (IDC), which has a ceiling value of up to $146.3 million over 7 years. The contract is focused on...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9.5M definitive contract to the University of Chicago on September 30, 2024, under the Vaccine Adjuvant Discovery Program (VADP). This cost-no-fee contract, which extends through September 29, 2029, supports research conducted at the university's Chicago, Illinois campus. The award represents a bilateral modification to descope the program for FY2025 cost savings, as indicated by the contract's stated objective of...
- This federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the U.S. Department of Health and Human Services, to the University of Georgia Research Foundation, Inc. (UGA Research Foundation) as the prime contractor. The contract, titled "ANIMAL MODELS OF INFECTIOUS DISEASES," has a ceiling value of $225,672.00 and was awarded on September 1, 2013 with a completion date of August 31, 2014. The contract is a Delivery Order under the...
This is a $61,272,508.00 federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of Chicago for research and development activities. The contract does not have a set-aside designation, indicating the University of Chicago was selected as a prime contractor for this effort based on its extensive expertise and capabilities in this domain. The contract supports the evaluation and development of animal and animal replacement models for screening and assessing candidate countermeasures such as therapeutics, vaccines, and diagnostics targeting priority infectious agents, including emerging viruses, antimicrobial resistant pathogens, and neglected tropical diseases. This work is being conducted under a larger $146.3 million indefinite delivery vehicle (IDV) contract awarded to the University of Chicago by NIAID in July 2024. The contract is divided into four task areas covering small animal models, non-human primate models, animal replacement and non-traditional animal models, and specialized reagent generation and distribution. This enables NIAID to issue task orders to the University of Chicago for specific studies assessing the safety, efficacy, and pharmacology of medical countermeasures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| 11 | Supplemental Agreement for work within scope | $790.0k | 7/27/09 | |
| 10 | Funding Only Action | $2.6m | 6/11/08 | |
| 9 | Other Administrative Action | $0 | 12/13/07 | |
| 8 | Funding Only Action | $2.6m | 5/31/07 | |
| 7 | Other Administrative Action | $0 | 5/29/07 |